{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:18:02Z","timestamp":1791249482203,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T00:00:00Z","timestamp":1408665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>37 is cell surface tetraspanin present on normal and malignant B cells. Otlertuzumab (<jats:styled-content style=\"fixed-case\">TRU<\/jats:styled-content>\u2010016) is a novel humanized anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>37 protein therapeutic. Patients with relapsed or refractory follicular non\u2010Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>), mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>), or Waldenstr\u00f6m's macroglobulinaemia (<jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content>) received otlertuzumab at 20\u00a0mg\/kg administered intravenously once a week for up to 8\u00a0weeks followed by 4\u00a0monthly doses. Sixteen patients were treated; median age was 62\u00b75\u00a0years (range, 41\u201381), and median number of prior regimens was 4 (range, 1\u20137). Twelve patients were refractory to prior treatment, 5 were refractory to rituximab. The mean terminal half\u2010life was 9\u00b75\u00a0days. Lymph node reduction of \u226550% by computerized tomography scan measurements was seen in 3 of 12 patients, including one <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> patient who had a partial response. One <jats:styled-content style=\"fixed-case\">WM<\/jats:styled-content> patient had a minor response. The most frequent adverse events were neutropenia, fatigue, nausea, thrombocytopenia, diarrhoea, and peripheral oedema; most were grade 1\/2. Otlertuzumab treatment appears to have been well tolerated by the patients in this study. Clinical activity was observed in this small heterogeneous cohort of highly refractory, heavily pretreated B\u2010cell non\u2010Hodgkin lymphoma patients. These data suggest that further clinical investigation in non\u2010Hodgkin lymphoma is warranted.<\/jats:p>","DOI":"10.1111\/bjh.13099","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T11:05:37Z","timestamp":1408705537000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Otlertuzumab (<scp>TRU<\/scp>\u2010016), an anti\u2010<scp>CD<\/scp>37 monospecific <scp>ADAPTIR<\/scp><sup>\u2122<\/sup> therapeutic protein, for relapsed or refractory <scp>NHL<\/scp> patients"],"prefix":"10.1111","volume":"168","author":[{"given":"John M.","family":"Pagel","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Spurgeon","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Oregon Health &amp; Science University Knight Cancer Institute Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Division of Hematology and Comprehensive Cancer Center The Ohio State University Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Georgia Regents University Augusta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Lanasa","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Eisenfeld","sequence":"additional","affiliation":[{"name":"Emergent Product Development Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Stromatt","sequence":"additional","affiliation":[{"name":"Emergent Product Development Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center University of Washington Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood.V116.21.3931.3931","article-title":"TRU\u2010016, An Anti\u2010CD37 SMIPTM Biologic, In Combination with Other Therapeutic Drugs In Models of Non\u2010Hodgkin's Lymphoma","volume":"116","author":"Algate P.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403822"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1200\/jco.2009.27.15_suppl.8571","article-title":"Evaluation of the effect of TRU\u2010016, an anti\u2010CD37 directed SMIP in combination with other therapeutic drugs in models of non\u2010Hodgkin's lymphoma","volume":"27","author":"Baum P.R.","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_5_1","first-page":"4483","article-title":"Immunophenotyping of leukemias using a cluster of differentiation antibody microarray","volume":"61","author":"Belov L.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-512137"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/96.2.184"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(92)90092-H"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30153"},{"key":"e_1_2_9_11_1","first-page":"156","article-title":"Rituximab in diffuse large B\u2010cell lymphoma","volume":"2","author":"Coiffier B.","year":"2004","journal-title":"Clinical Advances in Hematolology and Oncology"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210376"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2007.10.008"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0055"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.11.1696"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0876"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.03.040"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257485"},{"key":"e_1_2_9_19_1","first-page":"2327","article-title":"Pharmacokinetics of therapeutic monoclonal antibodies used in oncology","volume":"25","author":"Leveque D.","year":"2005","journal-title":"Anticancer Research"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4049\/jimmunol.137.9.3013","article-title":"A unique antigen on mature B cells defined by a monoclonal antibody","volume":"137","author":"Link M.P.","year":"1986","journal-title":"Journal of Immunology"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711520103"},{"key":"e_1_2_9_22_1","first-page":"225","article-title":"Detailed phenotypic analysis of B\u2010cell lymphoma using a panel of antibodies reactive in routinely fixed wax\u2010embedded tissue","volume":"128","author":"Norton A.J.","year":"1987","journal-title":"The American journal of Pathology"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12102"},{"key":"e_1_2_9_24_1","first-page":"181","article-title":"Immunophenotypic criteria for the diagnosis of non\u2010Hodgkin's lymphoma","volume":"128","author":"Picker L.J.","year":"1987","journal-title":"The American Journal of Pathology"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.8.1027"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.009"},{"key":"e_1_2_9_27_1","first-page":"140","article-title":"Immunophenotyping of non\u2010Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology","volume":"129","author":"Schuurman H.J.","year":"1987","journal-title":"The American Journal of Pathology"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4049\/jimmunol.140.3.905","article-title":"The B cell\u2010associated CD37 antigen (gp40\u201052). Structure and subcellular expression of an extensively glycosylated glycoprotein","volume":"140","author":"Schwartz\u2010Albiez R.","year":"1988","journal-title":"Journal of Immunology"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910515)67:10<2579::AID-CNCR2820671030>3.0.CO;2-H"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900070104"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0833"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548560"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-062927"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13099","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.13099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:54:38Z","timestamp":1696326878000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/bjh.13099"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13099","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,22]]},"assertion":[{"value":"2014-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-07-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}